



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



## Original article

## Prospective Latin American cohort evaluating outcomes of patients with COVID-19 and abnormal liver tests on admission



Manuel Mendizabal<sup>a,b,\*</sup>, Federico Piñero<sup>a,b,1</sup>, Ezequiel Ridruejo<sup>b,c,1</sup>, Margarita Anders<sup>b,d</sup>, María Dolores Silveyra<sup>e</sup>, Aldo Torre<sup>f</sup>, Pedro Montes<sup>g</sup>, Alvaro Urzúa<sup>h</sup>, Josefina Pages<sup>a,b</sup>, Luis G. Toro<sup>i</sup>, Javier Díaz<sup>j</sup>, Esteban Gonzalez Ballerga<sup>k</sup>, Godolfino Miranda-Zazueta<sup>l</sup>, Mirta Peralta<sup>b,m</sup>, Isabel Gutiérrez<sup>f</sup>, Douglas Michelato<sup>n</sup>, Maria Grazia Venturelli<sup>o</sup>, Adriana Varón<sup>b,p</sup>, Emilia Vera-Pozo<sup>q</sup>, Martín Tagle<sup>r</sup>, Matías García<sup>c</sup>, Alfredo Tassara<sup>d</sup>, Julia Brutti<sup>e</sup>, Sandro Ruiz García<sup>s</sup>, Carla Bustios<sup>t</sup>, Nataly Escajadillo<sup>u</sup>, Yuridia Macias<sup>v</sup>, Fátima Higuera-de la Tijera<sup>w</sup>, Andrés J Gómez<sup>x</sup>, Alejandra Dominguez<sup>y</sup>, Mauricio Castillo-Barradas<sup>z</sup>, Fernando Contreras<sup>A</sup>, Aldana Scarpin<sup>c</sup>, Maria Isabel Schinoni<sup>b,B</sup>, Claudio Toledo<sup>C</sup>, Marcos Giralda<sup>D</sup>, Victoria Mainardi<sup>E</sup>, Abel Sanchez<sup>F</sup>, Fernando Bessone<sup>G</sup>, Fernando Rubinstein<sup>H</sup>, Marcelo O Silva<sup>a,b</sup>

<sup>a</sup> Hepatology and Liver Transplant Unit, Hospital Universitario Austral, Pilar, Argentina

<sup>b</sup> Latin American Liver Research Educational and Awareness Network (LALREAN)

<sup>c</sup> Liver Section, Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires Argentina

<sup>d</sup> Hepatology and Liver Transplant Unit, Hospital Alemán, Buenos Aires, Argentina

<sup>e</sup> Department of Internal Medicine, Sanatorio Anchorena, Buenos Aires, Argentina

<sup>f</sup> Department of Internal Medicine, Centro Médico ABC, Ciudad de México, México

<sup>g</sup> Gastroenterology Unit, Hospital Nacional Daniel A. Carrión, Callao, Perú

<sup>h</sup> Gastroenterology Section, Internal Medicine Department, Hospital Clínico de la Universidad de Chile, Santiago, Chile

<sup>i</sup> Hepatology and Liver Transplant Unit, Hospitales de San Vicente Fundación de Medellín y Rionegro, Medellín, Colombia

<sup>j</sup> Hospital Nacional Edgardo Rebagliati Martins, Lima, Perú

<sup>k</sup> Department of Gastroenterology, Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, Buenos Aires, Argentina

<sup>l</sup> Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición, Ciudad de México, México

<sup>m</sup> Intensive Care Unit, Hospital de Infecciosas Francisco J Muñiz, Buenos Aires, Argentina

<sup>n</sup> Hospital Especializado en Enfermedades Infecciosas Instituto Couto Maia, Salvador de Bahía, Brazil

<sup>o</sup> Gastroenterology Unit, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Perú

<sup>p</sup> Liver Unit, Fundación Cardio-Infantil, Bogotá, Colombia

<sup>q</sup> Hospital Regional Dr. Teodoro Maldonado Carbo del IESS, Guayaquil, Ecuador

<sup>r</sup> Gastroenterology Unit, Clínica Anglo-Americana, Lima, Perú

<sup>s</sup> Gastroenterology Unit, Hospital de Víctor Lazarte Echegaray, Trujillo, Perú

<sup>t</sup> Gastroenterology Unit, Clínica Delgado, Lima, Perú

<sup>u</sup> Gastroenterology Unit, Hospital Nacional Almanzor Aguinaga Asenjo, Chiclayo, Perú

<sup>v</sup> Department of Medicine, IMSS Hospital General Regional No.1 "Dr. Carlos Mc Gregor Sánchez", Ciudad de México, Mexico

<sup>w</sup> Department of Gastroenterology and Hepatology, Hospital General de México "Dr. Eduardo Liceaga", Ciudad de México, México

<sup>x</sup> Endoscopy and Transplant Service, Hospital Universitario Fundación Santa Fé de Bogotá, Bogotá, Colombia

<sup>y</sup> Department of Gastroenterology, Hospital Padre Hurtado, Santiago, Chile

<sup>z</sup> Gastroenterology Unit, Hospital de Especialidades del Centro Médico Nacional La Raza IMSS, Ciudad de México, México

<sup>A</sup> Department of Gastroenterology, CEDIMAT, Santo Domingo, Dominican Republic

<sup>B</sup> Department of Gastroenterology, Hospital Alianza, Bahía, Brazil

<sup>C</sup> Gastroenterology Unit, Hospital Valdivia, Universidad Austral de Chile, Valdivia, Chile

\* Corresponding author at:

E-mail address: [mmendizaba@cas.austral.edu.ar](mailto:mmendizaba@cas.austral.edu.ar) (M. Mendizabal).

<sup>1</sup> Equally contributed as first authors.

<https://doi.org/10.1016/j.aohep.2020.100298>

1665-2681/© 2020 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

<sup>D</sup> Department of Gastroenterology, Hospital de Clínicas, Universidad Nacional de Asunción, Asunción, Paraguay<sup>E</sup> Hepatology and Liver Transplant Unit, Hospital Central De las Fuerzas Armadas, Montevideo, Uruguay<sup>F</sup> Department of Gastroenterology, Hospital Roosevelt, Ciudad de Guatemala, Guatemala<sup>G</sup> Department of Gastroenterology, Hospital Provincial del Centenario, Rosario, Argentina<sup>H</sup> Instituto de Efectividad Clínica y Sanitaria, Buenos Aires, Argentina

## ARTICLE INFO

## Article history:

Received 17 November 2020

Accepted 2 December 2020

Available online 7 January 2021

## Keywords:

SARS-CoV-2

Death

Pandemic

Hepatitis

Coronavirus

## ABSTRACT

**Introduction & objectives:** The independent effect of liver biochemistries as a prognostic factor in patients with COVID-19 has not been completely addressed. We aimed to evaluate the prognostic value of abnormal liver tests on admission of hospitalized patients with COVID-19.

**Materials & methods:** We performed a prospective cohort study including 1611 hospitalized patients with confirmed SARS-CoV-2 infection from April 15, 2020 through July 31, 2020 in 38 different Hospitals from 11 Latin American countries. We registered clinical and laboratory parameters, including liver function tests, on admission and during hospitalization. All patients were followed until discharge or death. We fit multivariable logistic regression models, further post-estimation effect through margins and inverse probability weighting.

**Results:** Overall, 57.8% of the patients were male with a mean age of 52.3 years, 8.5% had chronic liver disease and 3.4% had cirrhosis. Abnormal liver tests on admission were present on 45.2% (CI 42.7–47.7) of the cohort (n = 726). Overall, 15.1% (CI 13.4–16.9) of patients died (n = 244). Patients with abnormal liver tests on admission presented higher mortality 18.7% (CI 15.9–21.7), compared to those with normal liver biochemistries 12.2% (CI 10.1–14.6); P < .0001). After excluding patients with history of chronic liver disease, abnormal liver tests on admission were independently associated with death [OR 1.5 (CI 1.1–2.0); P = 0.01], and severe COVID-19 (2.6 [2.0–3.3], P < .0001), both adjusted by age, gender, diabetes, pneumonia and body mass index >30.

**Conclusions:** The presence of abnormal liver tests on admission is independently associated with mortality and severe COVID-19 in hospitalized patients with COVID-19 infection and may be used as surrogate marker of inflammation.

Clinicaltrials.gov: NCT04358380.

© 2020 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## 1. Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causing Coronavirus disease 2019 (COVID-19) has been associated with high mortality. The factors commonly associated with worse prognosis are age greater than 60 years, presence of diabetes, cardiovascular disease, and obesity [1,2]. While SARS-CoV-2 is known to cause mainly pulmonary disease, the emerging literature suggests that many extrapulmonary manifestations of COVID-19 can also be present [3].

The liver might also represent a target organ for SARS-CoV-2 based on the findings that angiotensin-converting enzyme (ACE-2), the major receptor of SARS-CoV-2, is expressed on cholangiocytes [4]. Liver abnormalities could be due to hypoxia-associated metabolic derangements, drug-induced liver injury and hyperinflammation observed during cytokine storm, causing direct cytopathic damage to the liver [5–7]. A recent systematic review reported a 19% (range 1–53%) pooled prevalence of liver function abnormalities in COVID-19 patients [6,8]. However, studies reporting liver injury in COVID-19 patients are retrospective, with high clinical and statistical heterogeneity [6,9–13]. Most of these studies described a substantial increase in the incidence of liver injury after hospitalization. However, the impact of liver biochemistry parameters on admission, and the clinical course of COVID-19 remains uncertain. Hence, in hospitalized patients with COVID-19, whether abnormal liver tests on admission may be surrogate markers of inflammation and an independent prognostic factor is still unknown.

Because of a later arrival of the COVID-19 pandemic in Latin America, we had a unique opportunity to build a multi-national prospective registry. Thus, we sought to evaluate the effect of abnormal liver parameters on admission on COVID-19 disease severity and mortality.

## 2. Patients and methods

## 2.1. Study design, setting and participating centers

This prospective cohort study was performed from April 15, 2020 through July 31, 2020 in 38 different Hospitals from Argentina, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guatemala, Mexico, Paraguay, Peru and Uruguay. The study was supported and coordinated by the Latin American Association for the Study of the Liver (ALEH), Viral Hepatitis Group of Interest and registered in an open public registry (NCT04358380; [www.clinicaltrials.gov](http://www.clinicaltrials.gov)). Each Ethics Committee from all the participating centers approved the study protocol, and was exempted from the need for informed consent from patients. The protocol followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [14]. The study followed ethical standards (institutional and national) and those mandated by the Helsinki Declaration of 1975, as revised in 2008. All authors had access to the study data, reviewed, and approved the final version of this manuscript.

## 2.2. Cohort characteristics and study variables

Eligibility criteria for enrolment included patients  $\geq 17$  years old, hospitalized with SARS-CoV-2 infection confirmed by the real-time polymerase method (RT-PCR) as per the local site-specific protocol. In asymptomatic cases, a nasopharyngeal swab was obtained according to surveillance algorithms from each country (i.e. contact with positive subjects). We also included patients admitted for a different condition and tested positive for COVID-19 during their hospitalization. Patients with high-clinical and epidemiological suspicion of SARS-CoV-2 but without RT-PCR testing were excluded. All eligible patients were enrolled at each clinical

**Table 1**  
Baseline characteristics of patients hospitalized for COVID-19.

Variable	Total	Liver biochemistries		P
		Normal	Abnormal	
	N = 1611	N = 882	N = 729	Value
Age, years (mean, ± SD)	52.3 (17.4)	50.7(18.2)	54.2 (16.1)	0.0001
Male sex, n (%)	931 (57.8)	467 (52.9)	464 (63.6)	<.0001
Comorbidities, n (%)				
Hypertension	483 (29.9)	239 (27.1)	244 (33.5)	0.006
Diabetes	286 (17.7)	140 (15.9)	146 (20.0)	0.03
COPD/asthma	95 (5.9)	54 (6.1)	41 (5.7)	0.7
Cardiac disease	108 (6.7)	61 (6.9)	47 (6.4)	0.7
Cerebrovascular disease	33 (2.1)	24 (2.8)	9 (1.1)	0.03
HIV	16 (0.9)	6 (0.7)	10 (1.4)	0.2
Cancer	69 (4.3)	38 (4.3)	31 (4.2)	0.9
Chronic kidney disease	43 (2.8)	21 (2.4)	22 (3.0)	0.4
Body Mass Index >30	277 (17.2)	125 (14.2)	152 (20.8)	<.0001
Tobacco use, n (%)	326 (20.2)	178 (20.2)	148 (20.3)	0.9
Pregnant, n (%)	26 (1.6)	14 (1.6)	12 (1.6)	0.9
Solid organ transplant recipient, n (%)	23 (1.4)	10 (1.0)	13 (1.9)	0.3
Chronic liver disease, n (%)	135 (8.5)	39 (4.4)	98 (13.4)	<.0001
Cirrhosis, n (%)	55 (3.4)	15 (1.7)	40 (5.5)	<.0001
Medications before admission				
Antibiotics, n (%)	180 (11.7)	71 (8.0)	109 (14.9)	<.0001
NSAIDs – paracetamol, n (%)	209 (12.9)	103 (11.7)	106 (14.5)	0.09
ACE-2 inhibitors, n (%)	188 (11.7)	99 (11.3)	89 (12.1)	0.6
Laboratory parameters on admission				
Hemoglobin, mg/dL, mean (± SD)	13.7 (2.1)	13.7 (2.0)	13.8 (2.2)	0.4
WBC/mm <sup>3</sup> , mean (± SD)	8310 (5058)	7360 (4142)	9460 (5780)	<.0001
Lymphocyte count <1500/mm <sup>3</sup> , n (%)	1031 (66.5)	528 (59.8)	503 (68.9)	<.0001
Platelets, ×10 <sup>9</sup> /L, mean (± SD)	235.4 (97.7)	224.8 (86)	248.1(108)	<.0001
Albumin, mg/dL, mean (± SD) <sup>a</sup>	3.9 (0.6)	4.0 (0.5)	3.7 (0.6)	<.0001
INR, mean (± SD)	1.1 (0.3)	1.0 (0.2)	1.1 (0.4)	0.0004
Creatinine, mg/dL mean (± SD)	1.02 (0.9)	1.0 (0.9)	1.0 (0.8)	0.7
Ferritin ng/mL, mean (± SD) <sup>b</sup>	785 (922)	551 (624)	1083 (1131)	<.0001
C-Reactive Protein mg/dL, mean (± SD) <sup>c</sup>	49.7 (83.8)	32.6 (2.6)	68.7 (96.6)	<.0001

Abbreviation: ACE-2, angiotensin-converting enzyme; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus, INR, international normalized ratio; NSAIDs, non-steroidal anti-inflammatory drugs.

<sup>a</sup> 1488 observations.

<sup>b</sup> 920 observations.

<sup>c</sup> 1142 observations.

site. Study data were prospectively registered into a web-based electronic system. All patients were followed until discharge or death.

### 2.3. Liver function tests and other exposure variables on admission and during hospitalization

We collected epidemiological, demographic, clinical, routine laboratory, radiological and treatment regimen data on each patient on admission. Data about medication use before hospitalization was collected, including antibiotics, non-steroidal anti-inflammatory drugs, acetaminophen and ACE-2 inhibitors. Laboratory parameters included inflammatory markers such as C-reactive protein and ferritin levels. Lymphopenia was considered when an absolute lymphocyte count was less than 1500/mm<sup>3</sup> [15].

To identify specific clinical and laboratory features in patients with abnormal liver biochemistry parameters, enrolled cases were categorized into two groups (with or without abnormal liver biochemistry values on admission). We defined abnormal liver tests as the elevation of total bilirubin, alanine aminotransferase (ALT) or alkaline phosphatase (ALP) over the upper limit of normal (ULN). ULN was defined by the reference value from each institution. Given the lack of consensus on liver injury classification in COVID-19, we categorized the degree of ALT elevation as mild (<2 times ULN), moderate (2–5 times ULN) and severe (>5 times ULN), as it has been previously reported [9]. ALT was selected to represent liver affection rather than AST due to the more predominant extra-hepatic sources of AST, rendering it less liver-specific. Moreover, peak val-

ues of routine laboratory tests, including total bilirubin, ALT or ALP, were recorded during hospitalization.

### 2.4. COVID-19 severity

The severity of COVID-19 was classified based on clinical examination results, symptoms, chest radiography and medical support. Severe COVID-19 cases were defined as those who developed acute respiratory distress syndrome (ARDS), required intensive care unit (ICU) monitoring, and/or ventilatory support, as reported elsewhere [15,16].

### 2.5. Primary outcome, sample size calculations and statistical analysis

The primary end-point was overall mortality. Secondary outcome was development of severe COVID-19 during hospitalization. Based on previously reported mortality rates, a mean rate of 4.8% was estimated with a 95% CI 3.9–5.8% [15,17,18]. Assuming a type I error of 5% (P-value <0.05) and a type II error of 0.10 (90% power), and to follow the “1 variable per 10 primary events rule”, to include at least six independent variables in the final logistic regression model, a minimum of 1244 patients would be needed to obtain a minimum of 60 deaths. In addition, we calculated the proportion of patients presenting with abnormal liver tests on admission being 41.1% ± 17.1 [2,17,19].

Categorical data were compared using Fisher's exact test (2-tailed) or Chi-Square (X<sup>2</sup>) test as appropriate. Continuous variables were reported with a mean (± standard deviation, SD) or median

**Table 2**  
Clinical outcomes of patients hospitalized for COVID-19.

Variable	Total	Liver biochemistries on admission		P
		Normal	Abnormal	
	N = 1611	N = 882	N = 729	Value
Pneumonia, n (%)	864 (53.6)	409 (46.4)	455 (62.4)	<.0001
ARDS, n (%)	660 (40.9)	267 (30.3)	393 (53.9)	<.0001
Mild	203 (12.6)	102 (11.6)	101 (13.8)	
Moderate	194 (12.0)	66 (7.5)	128 (17.6)	
Severe	263 (16.3)	99 (11.2)	164 (22.5)	
Multiorgan failure, n (%)	301 (18.7)	102 (11.6)	199 (27.3)	<.0001
Concomitant infections, n (%)	340 (22.1)	149 (16.9)	191 (26.2)	<.0001
Bacterial	319 (19.8)	138 (15.6)	181 (24.8)	
Viral	13 (0.7)	8 (0.9)	5 (0.7)	
Fungal	24 (1.6)	10 (1.1)	14 (1.9)	
Highest level of care, n (%)				
Ward	1046 (64.9)	666 (75.5)	380 (52.3)	<.0001
Intermediate ICU	195 (12.2)	66 (7.5)	129 (17.7)	
ICU	370 (22.9)	150 (17.0)	220 (30.2)	
Any kind of oxygen support, n (%)	881 (54.7)	372 (42.2)	509 (69.8)	<.0001
Intubation, n (%)	292 (18.1)	115 (13.0)	177 (24.3)	<.0001
Hemodialysis, n (%)	61 (3.8)	25 (2.8)	36 (4.9)	0.03
Vasopressors, n (%)	194 (12.0)	73 (8.3)	121 (16.6)	<.0001

Abbreviations: ARDS, acute respiratory distress syndrome, ICU, intensive care unit.

(Interquartile ranges 25–75%, IQR) and compared with Student's T or Mann-Whitney U tests according to their respective distributions. We created dummies for ordinal variables were assessed. Multivariable logistic regression was used to evaluate the association between abnormal liver tests and the odds of death (OR) with corresponding 95% confidence intervals (CI) estimated. We first fit univariate models to evaluate crude effects on mortality of prior medical history, clinical and laboratory findings on admission, then outcomes and treatments prescribed during hospitalization. We constructed the final multivariable models including exposure variables with a p-value <0.05 in univariate analysis, using a step-by-step procedure, in order to develop a parsimonious model. The final model's performance was evaluated, including calibration (Hosmer- Lemeshow goodness-of-fit test) and discrimination power through the area under the receiving operator curve (AUROC). We estimated margins effects after multivariable logistic regression models and inverse probability weighting (IPW) to estimate the attributable risk of abnormal liver function tests on admission, adjusted on the mean values of the other independent covariates. Data were analyzed with STATA 13.0 (StataCorp, Texas, USA).

### 2.6. Sensitivity analysis

Two sensitivity analyses were conducted. As the presence of the underlying liver disease may also play a role in the association of abnormal liver tests with disease severity, we conducted a sensitivity analysis excluding patients with prior chronic liver disease, comprising cirrhosis. Finally, we excluded patients developing SARS-CoV-2 infection during hospitalization.

### 3. Results

A cohort of 1611 patients hospitalized with SARS-CoV-2 infection were enrolled in ALEH registry. Baseline characteristics of the study population are displayed in Table 1. Of the entire cohort, 7.7% (CI 6.5–9.2) were admitted for other reasons and acquired SARS-CoV-2 infection during hospitalization (n = 125), and in 3.0% (CI 2.2–4.0) of these patients diagnosis was made >6 days after admission (n = 49). Radiological signs on admission showed pneumonia in 53.6% of the cohort (n = 864). The most frequent radiological finding was bilateral ground-glass opacities and it was present in 35.1% of the patients (n = 536). Common signs and symp-

toms reported by patients are presented in Supplementary Table 1. Seventy-one (4.4%) patients were asymptomatic at presentation. Overall, 8.5% (CI 7.1–9.9) of the cohort had chronic liver disease (n = 135) and 3.4% (CI 2.5–4.4) had cirrhosis (n = 55). The most common etiologies of chronic liver disease were metabolic-associated fatty liver disease in 86 patients, alcohol induced in 14 cases, chronic hepatitis C in 8 individuals and cholestatic diseases in 10 subjects.

#### 3.1. Clinical features of patients with SARS-CoV-2 and abnormal liver tests on admission

Abnormal liver biochemistry parameters on admission were present on 45.2% of the cohort (CI 42.7–47.7). In those patients with chronic liver disease, the proportion of abnormal liver tests on admission was 71.5% (CI 63.2–78.9). Patients with elevated ALT, total bilirubin and ALP accounted for 35.3%, 6.3% and 19.4%; respectively. Among patients with elevated ALT, 32.6% of the cases presented moderate injury (2–5 times ULN) and 10.7% were severe (>5 times ULN). Moreover, the incidence of elevated ALT during hospitalization was 16.2% (CI 14.4–18.1). When compared to admitted patients with normal liver tests, the group of patients with elevated liver biochemistry values on admission were mostly men (52.9% vs. 63.6%; P < .0001), of older ages (50.7 ± 18.2 vs. 54.2 ± 16.1 years old; P = 0.0001), and presenting a higher proportion of hypertension (27.1% vs. 33.5%; P = 0.006) and body mass index >30 (14.2% vs. 20.8%; P < .0001) (Table 1).

Table 1 also describes laboratory tests results at admission. Compared to the normal liver biochemistry group, patients with abnormal tests results had significantly higher platelet counts, international normalized ratio, and a higher proportion of individuals presented a lymphocyte count <1500/mm<sup>3</sup> and lower levels of serum albumin. A higher proportion of patients presenting abnormal liver biochemistry parameters on admission were under antibiotic treatment (P < .0001) (Table 1). During hospitalization, specific COVID-19 treatment was prescribed in 43.8% of the cohort (n = 705) and was more commonly administered to patients with abnormal liver tests on admission (p < 0.0001). Other drugs frequently used for hospitalized patients with COVID-19, were also significantly more commonly prescribed to patients who presented abnormal liver biochemistry values on admission (Supplementary Table 2).

**Table 3**

Logistic regression analysis evaluating the primary outcome (death) adjusted for variables significantly associated with a higher risk of mortality on admission.

Baseline exposure variable	Mortality rate (95% CI)	Adjusted odds ratio (95% CI)	P
Age, years			
<50	6.4 (4.8–8.4)	–	–
50–65	14.7 (11.5–18.3)	1.8 (1.2–2.8)	0.003
>65	31.3 (26.9–36.0)	5.4 (3.7–8.0)	<.0001
Gender			
Male	17.0 (14.6–19.5)	1.5 (1.1–2.1)	0.006
Female	12.6 (10.2–15.4)	–	–
Diabetes mellitus			
Yes	27.3 (22.2–32.3)	1.6 (1.1–2.2)	0.007
No	12.5 (10.8–14.4)	–	–
Body mass index >30			
Yes	20.9 (16.3–26.2)	1.4 (1.02–2.1)	0.04
No	13.9 (12.0–15.8)	–	–
Pneumonia			
Yes	21.6 (18.9–24.5)	2.3 (1.6–3.2)	<.0001
No	7.6 (5.8–9.8)	–	–
Abnormal liver tests			
Yes	18.7 (15.9–21.7)	1.4 (1.06–1.9)	0.02
No	12.2 (10.1–14.6)	–	–

Note: Calibration ( $P=0.07$ , Hosmer-Lemeshow test). ROC curve 0.76 (CI 0.74–0.78).

### 3.2. Clinical outcomes of patients with SARS-CoV-2

The cumulative mortality rate in the overall cohort was 15.1% (CI 13.4–16.9) after a median time since admission of 10.0 (IQR 4.0–18.5) days ( $n=244$ ). Clinical outcomes are reported in Table 2. Severe COVID-19 was developed in 43.8% (CI 41.4–46.3) of the patients. When considering prognostic demographics and prior medical history, increasing age, male gender, obesity, cirrhosis, and diabetes mellitus were significantly associated with a higher risk of mortality (Supplementary Table 3). Adjusted for age patients developing ARDS OR 4.0 (CI 2.5–6.5;  $P<.0001$ ), requiring mechanical ventilation OR 2.9 (CI 2.5–6.5;  $P<.0001$ ) or with multiorgan failure OR 5.2 (CI 3.5–7.7;  $P<.0001$ ) had a higher risk of mortality.

### 3.3. Association of abnormal liver function tests with death and severe COVID-19

Mortality was significantly higher in patients with elevated liver tests results on admission compared to those with normal liver tests values (18.7% vs. 12.2%;  $P<.0001$ ). Patients with abnormal liver tests on admission required more ICU-level care ( $p<.0001$ ), developed more frequently severe COVID-19 during hospitalization (57.5% vs. 32.4%,  $P<.0001$ ), and required more days of hospitalization (10 [IQR 6–16] vs. 7 [IQR 5–12],  $P<.0001$ ).

We evaluated the effect of abnormal liver biochemistry values on admission on the risk of mortality adjusted for age, prior medical history, clinical presentation and other laboratory parameters. Abnormal liver tests on admission were significantly associated with death (OR 1.4, CI 1.06–1.9;  $P=0.02$ ) (Table 3). After excluding patients with history of chronic liver disease, abnormal liver tests on admission were still independently associated with death (OR 1.5, CI 1.1–2.0;  $P=0.01$ ), adjusted for age, gender, diabetes, and pneumonia on admission (Table 4). The model showed adequate calibration ( $P=0.19$ ) with an AUROC of 0.76 (CI 0.73–0.78) (Supplementary Figure 1). Moreover, evaluating the dose-dependent effect of elevated ALT on admission as a matter of causality, patients with severe ALT augmentation presented a 2-fold greater odds of death compared to those with mild ALT elevation (OR 2.0, CI 1.1–3.7);  $P=0.02$ ) (Table 5). In patients without chronic liver disease, the attributable mortality risk for abnormal liver tests was 3.8% (CI 0.7–7.9%;  $P=0.01$ ), considering mean values for other independent covariates. In the IPW analysis, abnormal liver tests had an absolute increased mortality rate of 3.4% (CI –0.01 to 7.0) when compared to those presenting normal liver tests.

Finally, we analyzed the association of abnormal liver biochemistry values on admission and development of severe COVID-19 during hospitalization. Patients having abnormal liver tests results have a ~2-fold greater odds of developing severe COVID-19 OR 2.4 (CI 1.9–3.1;  $P<.0001$ ), adjusted for age, male gender, diabetes mellitus, BMI > 30 and pneumonia (Supplementary Table 4). The model showed an AUROC of 0.83 (CI 0.81–0.85). Sensitivity analysis excluding patients with prior chronic liver disease, abnormal liver tests on admission were still independently associated with severe COVID-19 of 2.6 (CI 1.9–3.3;  $P<.0001$ ), adjusted for age, gender, diabetes, and pneumonia on admission (Table 6).

## 4. Discussion

Results from this large Latin America prospective cohort study describe that almost half of the patients hospitalized with COVID-19 presented abnormal liver tests on admission. However, most patients just showed mild liver biochemistry parameters elevation at the early stage of SARS-CoV-2 infection. Compared to patients with normal liver tests on admission, those who had abnormal liver test results were more frequently admitted to ICU, had a significantly higher probability of developing severe COVID-19, and higher odds of mortality, highlighting its importance as a marker of disease severity.

Wide variability in liver enzymes deviations in patients with COVID-19 can be secondary to the different considered cutoff values and to the time of liver tests evaluation. In our study, we used liver enzymes cutoffs as defined by the ULN of each participating institution. We intended to describe the impact of liver injury at the early stages of the disease. Thus, while most studies contemplated peak liver test values during hospitalization, we used liver test abnormalities at hospital admission [9,20,21]. The frequency of liver enzymes elevation during SARS-CoV-2 infection is directly related to the progression of the severity of the disease. Some authors have recommended longitudinal monitoring of hepatic transaminases, particularly in patients receiving clinical research treatments [21]. At advanced stages of COVID-19, liver test alterations can have a multifactorial origin. The combination of multiple prescribed drugs and the SARS-CoV-2-induced systemic inflammatory response can lead to liver injury. Thus, evaluating the impact of peak liver test abnormalities during hospitalization can provide misleading conclusions.

In our study, we found that abnormal liver biochemistry values on admission were significantly associated with outcomes

**Table 4**

Logistic regression analysis for the primary outcome (death) based on data at admission, excluding patients with chronic liver disease or cirrhosis (n = 137).

Baseline exposure variable	Mortality rate (95% CI)	Adjusted odds ratio (95% CI)	P
Age, years			
<50	6.1 (4.5–8.1)	–	–
50–65	12.7 (9.7–16.4)	1.6 (1.02–2.5)	0.04
>65	31.6 (26.7–36.6)	5.4 (3.6–8.0)	<.0001
Gender			
Male	16.2 (13.8–18.9)	1.6 (1.1–2.2)	0.007
Female	11.7 (9.3–14.5)	–	–
Diabetes mellitus			
Yes	27.7 (22.1–33.9)	1.8 (1.3–2.6)	0.001
No	11.7 (10.0–13.6)	–	–
Pneumonia			
Yes	20.5 (17.7–23.5)	2.2 (1.6–3.2)	<.0001
No	7.3 (5.5–9.5)	–	–
Abnormal Liver tests			
Yes	17.9 (15.0–21.1)	1.5 (1.1–2.0)	0.01
No	11.6 (9.5–14.0)	–	–

Note: Calibration (P = 0.19, Hosmer-Lemeshow test). ROC curve 0.76 (CI 0.73–0.78).

**Table 5**

Logistic regression analysis for the primary outcome (death) evaluating the severity of ALT elevation on admission. Odds Ratios (OR).

Baseline exposure variable	Mortality rate (95% CI)	Adjusted OR (95% CI)	P
Age, years			
<50	6.4 (4.8–8.4)	–	–
50–65	14.7 (11.5–18.3)	1.8 (1.2–2.7)	0.004
>65	31.3 (26.9–36.0)	5.4 (3.7–8.0)	<.0001
Gender			
Male	12.6 (10.2–15.4)	1.5 (1.1–2.1)	0.007
Female	17.0 (14.6–19.5)	–	–
Diabetes mellitus			
Yes	27.3 (22.2–32.3)	1.5 (1.1–2.1)	0.02
No	12.5 (10.8–14.4)	–	–
Obesity			
Yes	20.9 (16.3–26.2)	1.4 (1.02–2.1)	0.04
No	13.9 (12.0–15.8)	–	–
Cirrhosis			
Yes	38.2 (25.4–52.3)	2.2 (1.2–4.0)	0.01
No	14.3 (12.6–16.2)	–	–
Pneumonia			
Yes	21.6 (18.9–24.5)	2.3 (1.6–3.2)	<.0001
No	7.6 (5.8–9.8)	–	–
ALT elevation			
None	–	–	–
Mild	17.9 (14.3–22.0)	1.3 (0.9–1.8)	0.2
Moderate	18.1 (13.4–23.5)	1.4 (0.9–2.1)	0.1
Severe	24.4 (15.3–35.4)	2.0 (1.1–3.7)	0.02

Note: Calibration (P = 0.27, Hosmer-Lemeshow test). ROC curve 0.77 (CI 0.75–0.79).

**Table 6**

Logistic regression analysis for the secondary outcome (severe COVID-19) excluding patients with chronic liver disease or cirrhosis (n = 137). Odds Ratios (OR).

Baseline exposure variable	Severe COVID-19 (95% CI)	Crude OR (95% CI)	P	Adjusted OR (95% CI)	P
Age, years					
<50	28.9 (25.6–32.4)	–1.03 (1.02–1.04)	–	–	–
50–65	50.7 (45.8–55.7)	2.5 (2.0–3.3)	<.0001	1.5 (1.1–2.1)	0.005
>65	59.4 (54.2–64.5)	3.6 (2.8–4.7)	<.0001	2.7 (1.9–3.8)	<.0001
Gender					
Male	48.5 (45.1–51.9)	1.8 (1.4–2.2)	<.0001	1.7 (1.3–2.5)	<.0001
Female	34.4 (30.7–38.3)	–	–	–	–
Diabetes mellitus					
Yes	63.4 (57.0–69.6)	2.8 (2.1–3.7)	<.0001	1.6 (1.1–2.3)	0.007
No	38.5 (35.8–41.3)	–	–	–	–
Obesity					
Yes	70.3 (64.1–76.0)	4.0 (3.0–5.4)	<.0001	3.2 (2.3–4.7)	<.0001
No	37.2 (34.5–40.0)	–	–	–	–
Pneumonia					
Yes	65.6 (62.1–68.9)	9.5 (7.4–12.2)	<.0001	7.2 (5.5–9.4)	<.0001
No	16.7 (14.0–19.7)	–	–	–	–
Abnormal liver tests					
Yes	57.2 (53.2–61.1)	2.8 (2.3–3.4)	<.0001	2.6 (1.9–3.3)	<.0001
No	31.5 (28.4–34.8)	–	–	–	–

Note: ROC curve 0.83 (CI 0.81–0.85).

during hospitalization such as prolonged length of stay, development of severe COVID-19, and more importantly, death. A previous study from China reported similar findings describing an association between mortality and abnormal liver tests on admission [22]. However, in that study, data were retrospectively collected; patients in the abnormal liver tests group presented a significantly higher proportion of chronic liver disease. Lei et al. analyzed a large retrospective cohort from China, including more than 5700 patients [20]. In this interesting study, the authors concluded that the increase of AST levels had a higher correlation with mortality than other liver injury indicators. We believe that the inclusion of AST as a marker of liver injury is arguable due to the potential extra-hepatic sources of AST rendering it less liver-specific. To avoid potential confounders, we did not include AST in our definition of abnormal liver tests, and we performed a sensitivity analysis excluding patients with chronic liver disease, still observing a significant association to worse outcomes.

Compared to previous studies, our cohort includes a younger population with a lower proportion of associated comorbidities [1,9]. We can speculate that this is the consequence of including patients with mild symptoms of COVID-19 who were hospitalized because they could not isolate themselves at their homes. This allowed us to evaluate the whole spectrum of SARS-CoV-2 infection, from mild cases to those who developed severe COVID-19 and died. Therefore, the prognostic value of liver biochemistry tests would acquire greater relevance. We believe that liver function tests should be included in the initial evaluation of a COVID-19 patient, and may help physicians decide hospitalization or prompt referral irrespectively from radiological pneumonia.

The major strength of our study is the inclusion of a large and geographically diverse population, in which data collection and outcome measures have been prospectively collected. However, we must acknowledge certain limitations in the interpretation of the results of our study. First, the recommended cutoff for defining moderate or severe liver injury is debatable [23,24]. However, we are facing a new disease and its impact on the liver is not yet completely understood. We then graded liver injury by applying cutoff values previously reported in this disease [9]. Second, we did not include other inflammatory markers in our final model. We intended to include affordable and feasible blood tests, together with clinically relevant variables, to build a parsimonious model. Finally, although SARS-CoV-2 infection was diagnosed as per the local site-specific protocol, algorithms followed their local epidemiological situation and available resources.

In summary, in this large multicenter cohort from Latin America, abnormal liver tests on admission were associated with most severe clinical outcomes, including death. This accessible test may be another useful tool to identify patients at increased risk of developing severe COVID-19 who require hospitalization. Moreover, future clinical trials evaluating COVID-19 targeted therapies may consider abnormal liver tests as a stratifying factor for clinical outcomes.

#### Conflict of interest

None.

#### Funding

None.

#### Contributorship statement

Dr. Mendizabal and Dr. Piñero had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

*Concept and design:* Silva, Mendizabal, Ridruejo, Pagés and Piñero.

*Acquisition, analysis, or interpretation of data:* all authors.

*Drafting of the manuscript:* Mendizabal, Piñero, Ridruejo, Silva and Pagés.

*Critical revision of the manuscript for important intellectual content:* all authors.

*Statistical analysis:* Piñero, Rubinstein and Mendizabal.

*Supervision:* Ridruejo, Rubinstein, Silva.

#### Acknowledgements

We would like to thank ALEH's executive office for their invaluable help and support on this project, especially to Macarena Muñoz, María Jesús Marcone and Verónica García Huidobro.

Other authors who collaborated with the data Acquisition: Máximo Cattáneo<sup>h</sup>, Jonathan Aguirre Valadez<sup>i</sup>, Germán Rojas<sup>k</sup>, Edgar Ortiz-Brizuela<sup>11</sup>, Damián Conte (Hospital Privado de Córdoba, Argentina), Natalia Ratusnú (Hospital de Ushuaia, Argentina), Leyla Nazal (Clínica Las Condes, Chile), Diana Escobar (Fundación Valle de Lili, Colombia), Sarai Gonzalez Huezo (Centro Médico Issemym, Mexico).

#### References

- [1] Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. *BMJ* 2020;369:1–12, <http://dx.doi.org/10.1136/bmj.m1985>.
- [2] Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. *Jama* 2020;323:2052–9, <http://dx.doi.org/10.1001/jama.2020.6775>.
- [3] Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. *Nat Med* 2020;26:1017–32, <http://dx.doi.org/10.1038/s41591-020-0968-3>.
- [4] Qi F, Qian S, Zhang S, Zhang Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. *Biochem Biophys Res Commun* 2020;526:135–40, <http://dx.doi.org/10.1016/j.bbrc.2020.03.044>.
- [5] Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. *Lancet* 2020;395:1517–20, [http://dx.doi.org/10.1016/S0140-6736\(20\)30920-X](http://dx.doi.org/10.1016/S0140-6736(20)30920-X).
- [6] Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: abnormal liver function tests. *J Hepatol* 2020;73:566–74, <http://dx.doi.org/10.1016/j.jhep.2020.04.006>.
- [7] Aroniadis OC, DiMaio CJ, Dixon RE, Elmunzer BJ, Kolb JM, Mendelsohn R, et al. Current knowledge and research priorities in the digestive manifestations of COVID-19. *Clin Gastroenterol Hepatol* 2020;18:1682–4, <http://dx.doi.org/10.1016/j.cgh.2020.04.039>.
- [8] Mao R, Qiu Y, He JS, Tan JY, Li XH, Liang J, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* 2020;5:667–78, [http://dx.doi.org/10.1016/S2468-1253\(20\)30126-6](http://dx.doi.org/10.1016/S2468-1253(20)30126-6).
- [9] Phipps MM, Barraza LH, LaSota ED, Sobieszczyk ME, Pereira MR, Zheng EX, et al. Acute liver injury in COVID-19: prevalence and association with clinical outcomes in a large US cohort. *Hepatology* 2020;72:807–17, <http://dx.doi.org/10.1002/hep.31404>.
- [10] Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C, et al. Clinical features of COVID-19-related liver functional abnormality. *Clin Gastroenterol Hepatol* 2020;18:1561–6, <http://dx.doi.org/10.1016/j.cgh.2020.04.002>.
- [11] Meszaros M, Meunier L, Morquin D, Klouche K, Fesler P, Malezieux E, et al. Abnormal liver tests in patients hospitalized with Coronavirus disease 2019: should we worry? *Liver Int* 2020;40:1860–4, <http://dx.doi.org/10.1111/liv.14557>.
- [12] Qi X, Liu C, Jiang Z, Gu Y, Zhang G, Shao C, et al. Multicenter analysis of clinical characteristics and outcomes in patients with COVID-19 who develop liver injury. *J Hepatol* 2020;73:455–8, <http://dx.doi.org/10.1016/j.jhep.2020.04.010>.
- [13] Medetalibeyoglu A, Catma Y, Senkal N, Ormeci A, Cavus B, Kose M, et al. The effect of liver test abnormalities on the prognosis of COVID-19. *Ann Hepatol* 2020;19:614–21, <http://dx.doi.org/10.1016/j.aohp.2020.08.068>.
- [14] Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the reporting of observational studies in epidemiol-



- ogy (STROBE) statement: guidelines for reporting observational studies. *Lancet* 2007;370:1453–7, [http://dx.doi.org/10.1016/S0140-6736\(07\)61602-X](http://dx.doi.org/10.1016/S0140-6736(07)61602-X).
- [15] Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020;382:1708–20, <http://dx.doi.org/10.1056/NEJMoa2002032>.
- [16] Sarin SK, Lau GK, Zheng M-H, Ji D, Sherief Abd-Elsalam, Hwang J. Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; the APCOLIS Study (APASL COVID-19 Liver Injury Spectrum study). *Hepatol Int* 2020;14:690–700, <http://dx.doi.org/10.21203/RS.3.RS-36338/V1>.
- [17] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020;395:507–13, [http://dx.doi.org/10.1016/S0140-6736\(20\)30211-7](http://dx.doi.org/10.1016/S0140-6736(20)30211-7).
- [18] Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. *JAMA Cardiol* 2020;5:802–10, <http://dx.doi.org/10.1001/jamacardio.2020.0950>.
- [19] Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. *Lancet Gastroenterol Hepatol* 2020;5:428–30, [http://dx.doi.org/10.1016/S2468-1253\(20\)30057-1](http://dx.doi.org/10.1016/S2468-1253(20)30057-1).
- [20] Lei F, Liu YM, Zhou F, Qin JJ, Zhang P, Zhu L, et al. Longitudinal association between markers of liver injury and mortality in COVID-19 in China. *Hepatology* 2020;72:389–98, <http://dx.doi.org/10.1002/hep.31301>.
- [21] Bloom PP, Meyerowitz EA, Reinus Z, Daidone M, Gustafson J, Kim AY, et al. Liver Biochemistries in Hospitalized Patients With COVID-19. *Hepatology* 2020, <http://dx.doi.org/10.1002/hep.31326>, 0–3.
- [22] Fu Y, Zhu R, Bai T, Han P, He Q, Jing M, et al. Clinical features of COVID-19-Infected patients with elevated liver biochemistries: a multicenter, retrospective study. *Hepatology* 2020, <http://dx.doi.org/10.1002/hep.31446>.
- [23] Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. *Am J Gastroenterol* 2017;112:18–35, <http://dx.doi.org/10.1038/ajg.2016.517>.
- [24] Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seef LB. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. *Clin Chem* 2000;46:2050–68, <http://dx.doi.org/10.1093/clinchem/46.12.2050>.